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This work was aimed at the investigation of the use of near-infrared spectroscopy (NIRS) for the identification of
counterfeit drugs. The identification is based on the comparison of the NIR spectrum of a sample with typical
spectra of the authentic drug using multivariate modelling and classification algorithms (PCA/SIMCA). Initially,
NIRS was evaluated for spectrum acquisition of various drugs, selected in order to observe the diversity of
physico-chemical characteristics found among commercial products. The parameters which could affect the spectra
of a given drug (especially if presented in solid form) were investigated and the results showed that the first
derivative can minimise spectral changes associated with tablet geometry, physical differences in their faces and
position in relation to the probe beam. The power of NIRS in distinguishing among similar pharmaceuticals was
demonstrated and a protocol is proposed to construct a multivariate model and to include it in a library allowing
testing for drug authenticity. The methodology was evaluated with real samples of counterfeit drugs and was able
to recognise all those presenting changes in composition as false. The results show unequivocally the potential of
NIRS for rapid, on-site and non-destructive identification of counterfeit pharmaceuticals.
Introduction
The dissemination of counterfeit drugs is an escalating criminal
activity in many countries. Particularly in Brazil, a significant
increase in occurrences of counterfeit drugs in commerce has
been noted during the last 3 years. Many of the false products
collected in the market have their composition altered in terms
of both their active and inactive ingredients. Such practices can
pose a severe risk to the health of a patient. In view of this fact,
of great social importance, a faster, on-site, direct and non-
destructive analytical methodology is necessary for inspection
purposes.
Unfortunately, the conventional techniques employed for
pharmaceutical analysis and drug quality control, using high-
performance liquid chromatography (HPLC), do not present the
above characteristics, being more suitable for the control of
drug composition where a highly skilled technician will carry
out a long, destructive and costly procedure. On the other hand,
spectroscopic techniques have most of the desired character-
istics for drug inspection and detection of falsification. Among
the spectroscopic techniques, that based on the near-infrared
(NIR) spectral region1 has gained acceptance in many fields. In
the NIR region (750–2500 nm), it is possible to observe mainly
overtones and combinations of absorption bands normally
occurring in the mid-IR region and associated with the C–H, N–
H and O–H bonds present in organic molecules.2 The low
intensities of these spectral features are, in large part, compen-
sated by the notable recent advances in the instrumentation
associated with modern NIR spectrophotometers. The use of
non-moving components in the construction of NIR spec-
trophotometers has imparted the robustness and portability
necessary for field operation and use in less restrictive ambient
conditions. In this respect, two types of instrument can be
distinguished: those based on dispersive optics, which use
arrays of sensors,3,4 and those based on acoustic–optical tunable
filters (AOTF).5–7 Both approaches result in high wavelength
precision and high signal-to-noise ratios, necessary for the
qualitative and quantitative application of NIR spectroscopy.
Particularly the development of the ‘free-space’ concept for
diffuse reflectance measurements resulted in an outstanding
signal-to-noise ratio which is difficult to achieve when other
approaches are adopted for that type of measurement, of great
interest for monitoring solids.6
The use of NIR spectroscopy in the pharmaceutical industry
has been extensively described.8–17 The use of NIR spectros-
copy for the positive identification of pharmaceutical raw
materials and final products has been also described.8–12 Many
publications can be found reporting the quantitative use of the
technique for determination of the content of the active
ingredients of the drugs.13–17 The role of NIR in the pharmaceu-
tical industry has been reviewed recently.18 However, the
literature does not report specifically on the investigation of
parameters and protocols necessary in order to be able to use
NIR spectroscopy for the identification of counterfeit drugs.
The characterisation of a commercial drug rests on the
qualitative and quantitative performance of a given analytical
technique. For a technique such as NIR spectroscopy, these
characteristics are found to depend on powerful multivariate
chemometric tools such as principal component analysis (PCA)
and SIMCA19,20 classification regarding qualitative analysis.
Falsification can be produced simply by reducing the content of
the active ingredient of a medicine, by repackaging a product
whose shelf-life has expired or by coarse adulteration, effected
by placing inactive material such as sugar, starch or a placebo in
a tablet. On the other hand, true drugs should contain a nearly
fixed and predictable composition resulting from the correct
quantities of the active and inactive ingredients, necessary for
their therapeutic efficacy. In terms of their characterisation, it is
possible to confirm that a unique NIR spectrum showing slight
and accountable variations can be associated with a particular
commercial medicine found in a drugstore. The low tolerance in
quality control in the modern pharmaceutical industry ensures a
close comparison among different lots of drugs produced over a
long period of time. Therefore, the problem appears to be a
simple one: to identify whether a drug sample is or is not the
drug reported on the label, and to obtain and compare the NIR
spectrum of the sample with the spectrum (spectra) of the true
product stored in a suitable library. However, to proceed with
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the use of NIR spectroscopy for counterfeit drug identification,
the parameters affecting spectrum acquisition and an evaluation
of the distinguishing capabilities of the technique should be
investigated. It is also important to define the minimum number
of samples and the selection approach to include all the
expected spectral alterations in a model constructed for drug
identification. These studies are essential to guide in construct-
ing a spectral library of drugs and to impart the robustness
necessary for a positive drug identification.
This paper presents the results and conclusions obtained in
the evaluation of NIR spectroscopy for the identification of
false drugs. The main parameters affecting spectrum acquisition
and a protocol to assemble a library which can be used for
inspection purposes and the necessary chemometric support are
described. The proposed methodology was evaluated using




Two spectrophotometers (Brimrose Luminar 2000 and 2030)
based on acoustic–optical filter (AOTF) technology, sharing the
same controlling computer and software (Brimrose Snap 2.03)
and data acquisition electronics, were employed. The instru-
ments work in the dual beam approach correcting for light
source fluctuations. The Luminar 2000 scans the range
850–1800 nm and was employed for transmittance/absorbance
measurements of liquid medicines with a transflectance optical
bundle probe with a total optical path of 5 mm and with a
circular area of 0.5 cm2. The transmittance measurement is
converted into absorbance by the instrument software.
The Luminar 2030 scans the 1100–2400 nm spectral region
and was employed for diffuse reflectance measurements of solid
drugs. This instrument employs the “free space” concept, which
precludes the use of optical bundles or integrating spheres for
reflectance measurement. Solid samples are placed about 6 cm
away from the window of the instrument and the reflected
portion of the light is collected through the same window and
sent to the detector. The instrument was arranged as shown in
Fig. 1. A special sample holding device, shown in Fig. 1(II) and
(III), was constructed and assembled in an x–y–z positioning
device to study the effect of sample position on spectral
measurement. The device employs an iris for centring the
sample in the support under the probe light beam.
Each spectrum was stored as an average of 300 scans
(nominal resolution 2 nm at a rate of 15 scan s21) in the spectral
ranges above described. An average spectrum requires only 30
s to be obtained using either the Luminar 2000 or 2030
instrument. All spectra were obtained by using the internal
reference for ratioing the probe and reference beams.
Effect of the tablet face
The effect of the tablet face presented to the probe beam was
evaluated using Aspirina and Melhoral, both nominally contain-
ing 500 mg of acetylsalicylic acid. The Melhoral tablet also
contains 10 mg of caffeine. Both drugs are used for anti-thermal
and pain relief and have one face with the company mark
stamped on it and the other with a half-dose groove which might
cause a change in the reflectance measurement.
Effect of the sample position
The effect of the solid sample position in relation to the probe
beam coming from the spectrophotometer on the reflectance
spectral data was investigated by using 500 mg Aspirina tablets.
The position was initially fixed at the maximum reflectance
obtained for a 99% flat reflectance standard (Labsphere
Spectralon) with the same cross-sectional area as the tablet. A
set of 100 spectra were collected for 50 tablets with reflectance
measurements taken on both sides. Then, spectra were obtained
after 0.5 mm stepped displacements of the positioning device in
each of the x, y and z coordinates.
Effect of the ambient humidity
This effect was also investigated by using 500 mg Aspirina
tablets. The tablets were left overnight inside a desiccator. The
sample was then removed and placed in the positioning device.
Enough time was allowed for the surface humidity of the tablet
to reach equilibrium with that of the room held at 25 °C. On
average, about 2 h were necessary until the spectral data
presented no significant difference between four successive
scans obtained one after the other within 10 min. The ambient
humidity varied from 40 to 80%. Spectra were obtained and
stored for later comparison.
Drugs employed in the study
The commercial drugs listed in Table 1 were employed for the
various studies. They were selected to embrace much of the
variety found in drug presentations, shapes and formulations.
Some of them were chosen in order to evaluate a specific
property of NIR spectroscopy, as described in the Results and
discussion session. Counterfeit drugs, listed in Table 2 were
employed for final validation of the procedure for drug
identification.
Models for all commercial drugs were constructed by
principal component analysis (PCA) using at least 10 different
lots of the product acquired in different local pharmacies. At
least 25 samples were taken for each drug and, when presented
in the form of tablets, reflectance spectra were obtained for both
faces.
For liquid samples, which do not present any problem with
homogeneity, only 10 samples from different lots were
employed for model construction. The samples had their spectra
Fig. 1 NIR spectrophotometer arrangements. I, Overall view: A, trans-
mittance/absorbance module; B, transflectance probe; C, moving support
for solid samples; and D, “free space” reflectance module. II and III, side
and upper view of the support for solid samples, respectively. Drawings are
not to scale.





























































obtained after thermal equilibration with room temperature held
at 25 ± 0.5 °C.
Chemometric software
Chemometric treatment of the spectral data, modelling and
classification were performed by using the Unscrambler 7.5
software (CAMO, Oslo, Norway). This package provides PCA
and SIMCA algorithms, used for modelling and classification,
respectively. PCA treatment of a set of spectra will decompose
them into scores and loadings for each principal component
(PC). Usually, the first 3–4 PCs take into account most of the
information present in the spectral data set and the score values
found for the two first PCs are usually enough to cluster the
spectra belonging to the same drug and to distinguish them from
other NIR spectra of different drugs. If not indicated otherwise,
the number of PCs included in a model was established using
cross-validation (one out each time) and the explained data
variance until this reached the greatest value without including
the noise present in the spectral data.
First- and second-derivative spectra were obtained by the
Unscrambler 7.5 software employing the Savitzky–Golay
algorithm with five points in the second-order polynomial
fitting.
Results and discussion
In order to produce a robust library containing relevant NIR
spectral information for the multitude of drugs available to the
consumer, it is important to determine the performance of the
spectrophotometer which will be employed for drug classifica-
tion and to include all expected spectral variability, accepted for
a true drug, in the modelling.
The reflectance module employed shows a good performance
for most of the spectral range in which it can operate. The values
of the standard deviation of the reflectance over the spectral
range, obtained for 20 spectra taken for the same face of a 500
mg Aspirina tablet, fixed in the sample holder, showed that the
most reproducible region extends from 1200 to 2175 nm (mean
value of 45 3 1026 absorbance units). This corresponds to the
best performance of the instrument in the reflectance mode as
the influence of other parameters (such as removing and
replacing the tablet in the holder and composition variability) do
not contribute to the measurement.
The standard deviation for absorbance measurements of
aqueous liquid samples taken in the region 850–1800 nm
showed the same behaviour with an average value of 40 3 1026
aborbance units in the central region with some degradation of
the precision at the beginning and end of the spectral range. The
best region extends from 900 to 1600 nm. Transflectance
measurements of aqueous solutions are prone to change with
temperature. Therefore, the measurements were performed
under ambient temperature control within ±0.5 °C.
The effect of removing and replacing the same sample in the
holder and of using samples of 20 different batches, placed in
the holder with the tablet face randomly selected, was also
evaluated using Aspirina as a model. Fig. 2 shows the behaviour
of the scores distribution for the two first principal components
of PCA models obtained by using the original spectra (A) and
by using the first (B) and second (C) derivative. Most of the
effects are similar and manifest themselves as a shift of the
whole spectrum in relation to the reflectance axis as a result of
the sample geometric factors. Additional variability would
come from the natural change in the sample composition, which
can reach up to ±10% for certain drugs. This source of spectra
variability should ideally be the only one present during the true
drug model construction in order to restrict the variability of the
spectra to reflect solely the expected and acceptable variation of
sample composition from batch to batch. By applying the first
derivative [Fig. 2(B)], geometric effects were minimised and a
random distribution of the scores of the samples was obtained,
independently of the type of measurement made (same sample
fixed in the holder; taking and replacing the same sample with
the same face presented to the probe beam; or samples of
different batches placed randomly in the holder). This demon-
strates that the first derivative is effective in correcting for
additional unwanted variability coming from sample geometric
factors present in the original reflectance spectra set. The
second derivative, apparently, does not remove more of these
effects. For this reason, all the models developed and described
below employed the first-derivative spectra.
Effect of the sample position
The effect of the position of the sample in relation to the probe
beam in the reflectance module was investigated. The criteria to
Table 1 Drugs employed in the evaluation of NIR spectroscopy
Drug Presentation form Main active ingredient
Aspirina 500 mg Tablets Acetylsalicylic acid 
Aspirina 650 mg Tablets Acetylsalicylic acid
Melhoral 500 mg Tablets Acetylsalicylic acid
Doril 500 mg Tablets Acetylsalicylic acid
AAS 500 mg Tablets Acetylsalicylic acid





Ampicilina 500 mg Tablets Ampicillin
Ampicilina 500 mg
generic Tablets Ampicillin
Binotal 500 mg Tablets Ampicillin
Pressotec 5, 10, 20 mg Tablets Enalapril maleate









































































































































determine the tolerance with respect to displacement in the three
directions was to find the maximum displacement that keeps the
SIMCA classification model valid for 10 new samples of
Aspirina. The results show that the tolerance was ±3, ±3 and ±6
mm for the x, y and z coordinates, respectively, in relation to the
exit window of the reflectance module. The z coordinate
represents the vertical distance from the sample to the
spectrophotometer window.
Effect of the ambient humidity
Water present in the atmosphere surrounding the sample can be
adsorbed on its surface, affecting the NIR reflectance spectrum.
The effect is noted by the increase in the absorption in the
regions around 1450 and 1940 nm which are associated with the
first overtone of the strength and the combination band of the
O–H bond, respectively. Different drugs showed different
capabilities for water absorption. To consider the effect of the
ambient humidity in a classification model one can have two
options. The humidity can be kept constant in the ambient
surroundings where the spectrum is obtained and a sufficient
time waited until equilibrium is achieved, or the data set can
include the spectral changes induced by the absorbed humidity.
With the latter option, the model becomes more robust but
requires the use of samples with different absorbed humidity in
order to include the spectral changes generated by its alteration.
This latter procedure was evaluated for Aspirina in the present
work. The models include spectra obtained for solid drugs
exposed to an ambient humidity changing from the extremes
observed for the laboratory (40–80%, with temperature chang-
ing from 20 to 33 °C). A model constructed with a spectra set
obtained after equilibrium with fixed humidity will wrongly
classify a real drug as not belonging to its expected group if it
has been exposed to a different ambient humidity from that
employed for model construction. This was observed for the
Aspirina model.
The sample needs to be removed from its package and placed
in the instrument support in order to obtain its NIR reflectance
spectrum. The moisture on the surface of the sample should be
at a value included during the modelling stage for that drug. As
usually the drug is kept protected from the ambient humidity,
this means that the model should include at least a set of spectra
obtained during a time interval equal to or longer than that
necessary to obtain the reflectance spectra of the sample. The
spectrum is obtained in at most 2 min after the sample has been
Fig. 2 Distribution of the scores in the first and second principal
components for the original reflectance (A) and first (B) and second (C)
derivatives of 20 Aspirina spectra. 1, Scores for 20 reflectance spectra of the
same Aspirina tablet taken with the tablet fixed in the support; Ω, scores for
20 spectra for the same Aspirina tablet taken after removing it and replacing
it in the support with the same face showing to the probe beam; and 8,
scores for 20 spectra of 20 Aspirina tablets from different batches placed in
the sample support without any care in selecting the face probed by the light
beam.
Fig. 3 (A) Reflectance spectra of four different commercial drugs
containing 500 mg of acetylsalicylic acid in their formulations; and (B)
classification of drugs containing acetylsalicylic acid (500 mg). 1, Aspirina;
8, Melhoral; $, AAS; /, Doril. Solid symbols are used to show the
classification results for test samples of the four drugs. The significance
level for the Coomans plot is 95%.





























































removed from its package. Therefore, the model has to include
a set of spectra which contain information about the change in
the adsorbed humidity for at least 20 min of exposure with
spectrum acquired, for instance, each 2 min. Under normal
conditions, the laboratory humidity varies from 40 to 50%,
facilitating the model construction. However, the model will
become even more robust if the data set includes spectra
obtained with the drugs exposed to a wider range of ambient
humidity. In this case the model could be effective for drug
identification independently of the ambient humidity.
Estimated number of samples necessary to characterise a
commercial class of drug
Drugs are commercialised with some tolerance in their content
of the active principle. This tolerance can reach about ±10%.
Furthermore, the environmental conditions, such as the degree
of humidity under which the drug is packed, its presentation
form, the granule size of its components and the nature of these
components, can affect the NIR spectrum. Therefore, to
characterise the class of the drug a minimum number of spectra
must be presented to the modelling software, PCA and SIMCA,
in order to consider the natural variability found among the
composition of a given medicine.
As a model to help access the order of magnitude of the
number of spectra necessary to define a class, 200 spectra of 500
mg Aspirina tablets from 100 different lots where obtained for
both faces, under distinct ambient humidity, and classification
models were constructed by randomly selecting 10, 20, 50, 100
and 200 spectra of the set. An additional 20 spectra of different
samples of the same drug were employed for model evaluation.
The results show that at least 50 spectra must be present in the
training set in order to obtain a 100% correct classification for
the additional test set. The degree of correct classification
decreased to 90 and 80% when training sets containing 20 and
10 spectra were employed.
Obviously it is dangerous to conclude that 50 spectra
represent a universal number to ensure a good classification
model for any drug. On the other hand, this number can be used
as a guide with the aid that similar results have been reported
elsewhere.18 A robust enough model for drug inspection can
only be produced by testing and evaluation case by case. The
effect of changing the master spectrophotometer must be further
considered if the model is to be transferred and used in different
equipment.
Discriminating capability of NIR spectroscopy for drug
classification and identification
Chemical composition is characteristic for each pharmaceutical
and may change even if the same active principle is employed
in drugs manufactured by different companies. For example,
there are many drugs on the Brazilian market employing
acetylsalicylic acid as the active ingredient. The quantity varies
Fig. 4 Flow chart showing the proposed protocol for model construction aimed at the inspection of drugs and identification of counterfeit samples.





























































but at least four different brands, nominally containing 500 mg
of that active ingredient, were found. Two of them also contain
about 10 mg of caffeine as a coadjutant in addition to the main
active ingredient. In view of the slight differences in their
composition, these commercial drugs are suitable to be
employed for evaluation of the discriminating power of NIR
spectroscopy.
Fig. 3(A) shows the NIR reflectance spectra of the four drugs.
Classification models were constructed for the Aspirina and
Melhoral drugs as described in the Experimental section. The
SIMCA classification graph shown in Fig. 3(B) demonstrates
the high capability of classification even for drugs presenting
similar composition. Even when the composition is practically
the same, as in the case of AAS, Aspirina, Doril and Melhoral,
a distinction is possible, probably owing to the difference in the
composition of the inactive ingredients that can account for up
to 15% of the total mass of the tablet. This capability, confirmed
in this work, to discriminate among similar aspirin tablets had
been observed previously.12
In 1998, the inactive constituents (placebo) of Microvlar
were packed as the real drug and distributed in commerce. Such
a situation poses a real problem, requiring a high discriminatory
capacity for correct identification of the real and counterfeit
drug by differentiating between the contraceptive drug Micro-
vlar and its placebo. The drug contains only 0.22% of
levonorgestrel and 0.04% of ethinylestradiol. The tablet is
covered with a coating containing an orange dye which prevents
direct probing of the drug. Therefore, NIR spectroscopy cannot
be applied directly to a tablet. Some Microvlar tablets had this
external coating removed and were ground in a mortar. The
powder can be compared with the placebo, supplied in the same
form. Both were pressed to produce 400 mg tablets of the drug
or placebo. The results showed that, apart of slight spectral
differences between the real drug and its placebo, an un-
equivocal classification was obtained. An external test set of 10
new samples of placebo or Microvlar were correctly classified
in their class and none was classified in the wrong class. The
PCA model required nine principal components.
The examples described above are representative of the
potential of the NIR technique for the identification and
classification of drugs, even when the differences in the
composition are very small.
Suggested protocol to construct a classification model for
commercial drugs
Based on the results shown above, it is possible to suggest a
protocol to construct a robust model for the identification and
classification of commercial drugs, presented in very different
forms. Fig. 4 shows a flow diagram that establishes the steps
necessary to produce the classification model. In the present
study, different batches purchased in different pharmacies were
employed. This practice can ensure the identification and
elimination of a counterfeit drug eventually present among the
collected samples if its inclusion in the model is attempted.
Samples of at least 10 lots were included in model construction,
summing at least 50 spectra, as found necessary following the
results of the investigation described above. Humidity and
ambient temperature were controlled or their fluctuations were
included in the model.
Identification of counterfeit drugs
Twelve samples of known counterfeit drugs apprehended in
commerce were employed to evaluate the NIR spectroscopy
protocol,as suggest in Fig. 4, for drug identification. The models
were constructed following the protocol described above. The
drugs and the falsification criteria are listed in Table 2.
Among the samples were seven which contained the real drug
and which were considered false because the label was changed
to hide the fact that the drugs were free samples supplied by the
drug company. These samples are valuable to demonstrate that
the NIR technique can determine only the real content of the
drug. The other five samples contained gross adulterations of
composition in relation to the true drug. Fig. 5(A) and (B) show
an example of the NIR spectra and the Coomans classification
graph of a selected counterfeit drug for which the composition
did not match that expected for the true drug.
All drugs evaluated that presented alterations in their
composition were classified as false, and those containing the
expected composition were classified as true by the model.
Conclusion
This paper reports an incisive investigation on the use of NIR
spectroscopy with the objective of identifying counterfeit drugs.
A relatively simple protocol and well established chemometric
methods (PCA and SIMCA) were employed. The main
drawbacks relating to the use of NIR spectroscopy for drug
identification, were evaluated, such as humidity alteration,
sample position and sample face (for tablets). A simple protocol
to produce a robust model has been proposed and evaluated with
known counterfeit drugs.
NIR spectroscopy was shown to be capable of identifying
subtle alterations in drug composition, as exemplified by the
Fig. 5 (A) Reflectance spectra of the drug Femme showing the differences
between the real and counterfeit samples; (B) Coomans graph at the 95%
confidence level showing the correct classification of counterfeit samples
(Ω) as non-member of the real drug class (1).





























































group of drugs containing acetylsalicylic acid as active
ingredient and by the capability of distinguishing between true
Microvlar and its placebo. Although impossible to demonstrate,
such capability of distinguishing subtle alterations in drug
composition support the hypothesis that NIR spectroscopy can
gather enough information to avoid an erroneous classification
of any other drug in a model defined for a pre-selected
medicine.
The results were 100% correct, considering the classification
of known counterfeit drugs (all classified as false, when the
composition is distinct from that of the true drug) and for
classification of real drugs (when falsification was only due to
alterations in the label or package, with the composition being
identical with that expected for the true drug or when the real
drug was evaluated.
These results indicate a very good performance of NIR
spectroscopy when employed for drug identification and when
used as a tool for rapid, non-destructive testing. It is a direct
method capable of being used for drugs presented in many
different physical forms and with full potential for in-field drug
quality control and inspection.
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